PBLS

Parabilis Medicines, Inc.

Nasdaq· CIK 0001657677

$24.82 +0.38 (+1.55%)

Oct 26 4:00 PM ET · prev $24.44

Market cap

$3.3B

Mid cap

Consensus

Buy

91% Buy or better · 11 analysts

Median target

$40.00

+61% · range $40.00–45.00

Since first trade

−21.5%

from $31.60 · Jun 10

30 days

−23.8%

from $32.57

Range since listing

$22.75–41.73

−41% from high · low Oct 16

Avg volume 20D

1.06M

shares / day

Short interest

8.26M

≈6.8% of shares · +35.6%

Days to cover

4.8

at average volume

Insider net

+$441.4M

3 buyers · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 6 reports · 90 days

Balance 0 bearish · 3 bullish · 3 neutral oldest → newest, height = score

Avg score

·High conf. 5/6

Strongest BULLISH Parabilis Medicines reported updated Phase 1/2 data for zolucatetide in desmoid tumors at ESMO 2026, showing…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Jun 11 to Jun 15 3 days of insider buys: $434.5M by 3 insiders, avg $20.01
R Jun 16 RA Capital Management, a director and 10% owner, purchased 19.73M sh…
R Jun 29 Three insiders, including a director, a major 10% owner (RA Capital…
I Jun 30 11 funds open new positions (13F)
A Jul 6 3 analysts initiate
B Jul 20 to Jul 22 3 days of insider buys: $6.9M by 1 insider, avg $28.29
X Sep 30 Short interest jumps 35.6% to 8.26M
E Oct 24 FDA: Parabilis Medicines Presents Updated Phase 1/2 Data for Zo…

Signal stack

Where each data set points today.

InsidersBULLISH

3 insiders bought $441.4M. No open-market sales.
InstitutionsBULLISH

Q2 2026: 11 added (11 new), 0 trimmed or exited. Largest new: Ra Capital Management, $791.9M, Fmr $281.7M.
AnalystsBULLISH

10 of 11 rate it Buy or better. Every target is above the price.
Short sellersBUILDING

Short interest +35.6% to 8.26M shares. 4.8 days to cover, ≈6.8% of shares.
TrendDOWNTREND

27% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

$1.4B

in new stakes

Fund	Move	Shares	Value
RA CAPITAL MANAGEMENT, L.P.	NEW	28,933,371	$791.9M
FMR LLC	NEW	10,292,735	$281.7M
Alphabet Inc.	NEW	4,919,498	$134.6M
FARALLON CAPITAL MANAGEMENT, L.L.C.	NEW	2,368,200	$64.8M
VANGUARD PORTFOLIO MANAGEMENT LLC	NEW	1,302,479	$35.6M
VANGUARD CAPITAL MANAGEMENT LLC	NEW	1,156,962	$31.7M
JPMORGAN CHASE & CO	NEW	1,042,772	$30.4M
ALLIANCEBERNSTEIN L.P.	NEW	810,279	$22.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts

Buy 91% rate it Buy or better

Strong Buy5Buy5Hold1Sell0Strong Sell0

12-month targets · 5 analysts

$24.82 $40.00 $40.00 $45.00

Price is below the lowest target. Median implies +61%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Oct 22, 2026	HC Wainwright & Co. INITIATE	INITIATE	Buy
Jul 6, 2026	Guggenheim INITIATE	INITIATE	Buy
Jul 6, 2026	Leerink Partners INITIATE	INITIATE	Outperform
Jul 6, 2026	B of A Securities INITIATE	INITIATE	Buy

Insider ledger

Form 4

$441.4M

bought · 3 insiders

sold · 0 insiders

Date	Insider	Type	Value
Aug 22, 2026	Tendler Craig Director	AWARD	20,294 sh
Jul 22, 2026	RA CAPITAL MANAGEMENT, L.P. Director	BUY	$1.4M
Jul 21, 2026	RA CAPITAL MANAGEMENT, L.P. Director	BUY	$1.1M
Jul 21, 2026	RA CAPITAL MANAGEMENT, L.P. Director	BUY	$606.6K
Jul 21, 2026	RA CAPITAL MANAGEMENT, L.P. Director	BUY	$189.7K
Jul 20, 2026	RA CAPITAL MANAGEMENT, L.P. Director	BUY	$914.4K
Jul 20, 2026	RA CAPITAL MANAGEMENT, L.P. Director	BUY	$2.7M
Jun 15, 2026	SEBULSKY ALAN Director	BUY	$110.1K

Earnings setup

Estimates

−$0.38

EPS estimate, this quarter

Current-quarter EPS estimate

$0.000

90d

$0.000

60d

−$0.367

30d

−$0.367

−$0.380

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.38	-$0.45–-$0.25	-3.6%	$500.0K
Next Q	-$0.40	-$0.47–-$0.26	-5.3%	$1.0M
Current FY	-$2.58	-$3.09–-$1.63	-55.2%	$1.2M
Next FY	-$2.19	-$3.37–-$1.19	-15.1%	$4.8M

Short side

FINRA· Sep 30, 2026

8,261,483

shares short

+35.6%

vs prior settlement

4.8

days to cover

≈6.8%

of shares outstanding

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 24, 2026 Press

Parabilis Medicines reported updated Phase 1/2 data for zolucatetide in desmoid tumors at ESMO 2026, showing a 72.2%…

Impact 7/10

Oct 24, 2026 FDA

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450

Oct 19, 2026 Press

Parabilis Medicines announced an upcoming oral presentation at ESMO 2026 of updated Phase 1/2 data for zolucatetide in…

Impact 4/10

Sep 15, 2026 SEC

Parabilis Medicines, Inc. filed an 8-K with Item 7.01 (Regulation FD Disclosure) on a routine basis. The filing…

8-K — Impact 2/10

Sep 2, 2026 SEC

Parabilis Medicines disclosed the mutually agreed departure of Chief Medical Officer Fawzi Benzaghou, M.D., effective…

8-K — Impact 3/10

Aug 22, 2026 Insider

Tendler Craig was granted 20,294 shares